Obesity is a major contributor to illness and death, particularly due to cardiovascular disease, resulting in 18 million deaths annually. New anti-obesity medications (AOMs) are being used to address this issue. A recent study examines the impact of AOMs on cardiovascular complications in obese individuals. AOMs like semaglutide and tirzepatide have shown promise in reducing the incidence of cardiovascular disease in overweight individuals. The study focused on Medicare patients over 65 years, showing that AOMs reduced the risk of heart failure and other cardiovascular issues by 8%. Further research is needed to understand the mechanisms behind these benefits and improve access to AOMs.
Source link
Anti-obesity medications slash heart disease risk in obese patients, study finds
